The UAE’s reputation precedes itself across various sectors including trade, finance, sustainability, technology, and lately, healthcare. Recent surges in international patient demand pushed the city to establish the supply chains, healthcare infrastructure, and precision medicine to support the growing sector.
The industry is currently valued at USD 4.2 billion and is driven by a demand for innovative therapies. According to market analysts, the pharmaceutical industry is expected to see the fastest growing segment is generic drugs due to their affordability and adoption. The market is set to transform owing to advancements in technology, and evolving consumer preferences.
Expansion of Telemedicine
Rather than remain a sophisticated consumer of imported pharmaceuticals, the country is investing heavily to upgrade their infrastructures. The development of telemedicine services is an area of huge potential. Rapid adoption of e-prescriptions and increased accessibility of healthcare gives this sector huge room for growth.
Manufacturing and Distribution
Under the UAE Vision 2021 initiative, the nation has established standards for licensing, manufacturing, and distributing pharmaceuticals. The UAE now operates 23 manufacturing centres producing over 2,500 locally made medicines and the pace of new investment is accelerating.
One possible challenge facing the market is the strict regulatory frameworks regarding drug approval and distribution.
In May 2025, Mubadala Investment Company, Abu Dhabi’s strategic investment arm, launched Mubadala Bio, with a manufacturing capacity of over 2.5 billion tablets and capsules and 120 million units of IV solutions and injectables.
Sharjah has simultaneously announced three new factories specialising in respiratory products, eye drops, antibiotics, and first aid materials, incorporating AI-driven manufacturing technologies.
Medical Tourism
Patients are arriving from across the GCC, Africa, South Asia, and beyond, seeking specialised oncology treatments, elective surgeries, fertility procedures, and complex chronic disease management. This inbound patient flow has a direct pharmaceutical consequence.
International patients arriving for specialised treatment require specialised medicines such as biologics, targeted oncology therapies, injectable solutions, rare disease treatments, many of which were historically imported.
As patient volumes grow, so does the exposure to import dependency: delayed shipments, cold chain failures, and global supply shocks all become operational risks for healthcare providers.
Medical tourism is not uniform. The patients arriving in the UAE tend to cluster around high-complexity, high-cost conditions, and pharmaceutical investment is following the same concentrations.
Oncology is the clearest example. Oncology drugs represent the leading therapeutic segment, with revenues estimated at USD 377 million in 2025. AstraZeneca introduced its cancer therapy IMJUDO (tremelimumab) in the UAE in June 2023, making the country one of the first in the region to offer the treatment for non-small cell lung cancer and hepatobiliary cancers.
The rare diseases segment is growing and valued at USD 615.8 million in 2024, it is expected to more than double to USD 1.34 billion by 2030 driven by a combination of rising patient awareness and government support for treatments that address unmet medical needs.
Where to invest?
For investors and business development teams, the picture is straightforward: the UAE pharmaceutical market was valued at USD 4.73 billion in 2024 and is forecast to reach USD 7.38 billion by 2030 at a CAGR of 7.65%. The growth is anchored in demand from a growing population, a chronic disease burden, and a medical tourism sector.
The market has not yet reached maturity, leaving opportunities for international pharma companies, from early market access to the implementation of innovative telemedicine services.
Free zones such as Jebel Ali and Dubai Airport Free Zone offer favourable business environments, tax incentives, and streamlined customs procedures, attracting multinational corporations and pharmaceutical manufacturers to establish their presence in the UAE.
For companies evaluating where to build their next regional manufacturing footprint, or where to establish a Middle East distribution hub, the UAE is making a deliberate and well-founded case for itself. The question is less whether the opportunity is real, and more how quickly the window for early positioning will remain open.
For more trusted business news, market insights, and investment updates from the UAE and beyond, visit www.moneypetrol.com and stay ahead of the curve.
Watch & subscribe to MoneyPetrol podcasts on YouTube for in-depth conversations with industry leaders and decision-makers.
Follow us on Instagram for real-time updates, expert perspectives, and exclusive content.
